Bristol-Myers Squibb Company (BMY) $58.54
Bristol-Myers Squibb (BMY) currently navigates a choppy market, with its shares dipping below the 50-day moving average, yet a robust technical confluence score suggests underlying strength and potential for a near-term bounce.
52-wk High $62.89
📌 Investment Snapshot
- BMY trades at 16.9x earnings with a 4.30% dividend yield, valuing it at $119.5 billion.
- Q4 2025 revenue hit $12.50 billion, delivering $0.54 EPS.
- Robust technical confluence (90/100) points to a potential near-term bounce despite recent weakness.
- Analysts maintain a Hold consensus with a $62.72 mean target, suggesting 7.14% upside.
Bristol-Myers Squibb currently trades near its 50-day moving average, experiencing a slight pullback. While the stock’s technical setup appears strong with a 90/100 confluence score, the RSI has not yet reached oversold territory for a high-conviction entry.
| 📍 Entry Zone | $57.00 or below | 🛑 Stop-Loss | $55.50 |
| 📋 Adjust If | BMY reclaims $59.00 with volume exceeding 1.5x average, confirming buyer conviction. | ||
The Investment Case — Why Now?
Bristol-Myers Squibb finds itself at a pivotal juncture. The stock has pulled back 5.0% over the last month, dipping below its 50-day SMA, yet a striking 90/100 Technical Confluence Score signals strong underlying technical support. This divergence creates an interesting setup, as institutional interest appears to be building at these lower levels, evidenced by recent buy-side liquidity sweeps.
However, the looming patent cliff for key revenue drivers like Opdivo and Eliquis remains a significant headwind. The company’s ability to successfully navigate this period with new pipeline assets and strategic acquisitions will dictate its long-term trajectory. Any setbacks in clinical trials or regulatory approvals for its next-generation drugs could severely impact future revenue streams and investor sentiment.
🤔 Does BMY’s robust technical support outweigh the long-term uncertainty surrounding its patent cliff and pipeline execution?
🏢 Company Overview
| Detail | Value |
|---|---|
| Company | Bristol-Myers Squibb Company |
| Ticker / Exchange | BMY / NYSE |
| Sector / Industry | Healthcare / Drug Manufacturers – General |
| CEO | Giovanni Caforio |
| Founded / HQ | 1887 / New York, NY |
📈 Price Action & Technicals
Dead Cross
Inside VA
Buy-side sweep at $58.32 on March 24, 2026, indicating institutional interest at lower levels.
BMY currently trades just below its 50-day Simple Moving Average ($58.75), signaling short-term weakness, yet it remains comfortably above its 200-day SMA ($49.93), affirming a bullish long-term trend. This divergence suggests a potential retest of immediate support before a continuation of the broader uptrend.
The RSI at 37.7 indicates mild selling pressure but avoids oversold conditions, while the MACD’s dead cross (-0.28 below -0.09 signal) confirms recent bearish momentum. Despite a moderate ADX of 22.6, the -DI (29.1) exceeding +DI (21.6) underscores the current bearish lean, challenging the otherwise strong technical confluence score.
Price action finds strong support from the Anchored VWAP at $53.96, which BMY trades significantly above. Furthermore, the stock sits within the Value Area ($41.88-$61.21) and above the Volume Profile’s Point of Control ($45.66), suggesting price acceptance at current levels and a solid foundation.
Volume is running well below average (57%) during this pullback, which could indicate a lack of strong conviction from sellers. The presence of multiple recent buy-side liquidity sweeps, notably at $58.32, $59.25, and $60.65, reveals smart money accumulating shares on dips, aligning with the open bullish FVG between $57.69 and $58.64, which the price is currently retesting.
🤔 With conflicting signals from momentum indicators (MACD, ADX) versus strong structural support (VWAP, VP, Sweeps), which technical narrative holds more weight for BMY’s immediate future?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| BMY | Bristol-Myers Squibb | 16.9x |
| PFE | Pfizer Inc. | 12.5x |
| MRK | Merck & Co., Inc. | 18.2x |
| JNJ | Johnson & Johnson | 17.1x |
| LLY | Eli Lilly and Company | 50.5x |
| S&P 500 | Index Average | 21.0x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $12.50B | $0.54 | |
| Q3 2025 | $12.22B | $1.08 | |
| Q2 2025 | $12.27B | $0.64 | |
| Q1 2025 | $11.20B | $1.20 |
Bristol-Myers Squibb reported $1.6 billion in Free Cash Flow last quarter, providing ample capital for its attractive 4.30% dividend yield and potential strategic investments. This strong cash generation is crucial for navigating upcoming patent expirations and funding pipeline development.
🚀 Growth Drivers — What Moves the Stock
- Innovative Pipeline 🟢 Upside Surprise — BMY’s robust R&D pipeline, particularly in oncology and immunology, holds the potential for new blockbuster drugs to offset revenue declines from patent expirations. Success in late-stage trials could provide significant upside.
- Attractive Dividend Yield 🟡 Priced In — The company’s 4.30% dividend yield makes it an appealing choice for income-focused investors, providing a steady return even amidst market volatility. This yield is well-supported by consistent free cash flow.
- Strategic M&A 🟢 Upside Surprise — Bristol-Myers Squibb has a history of strategic acquisitions to bolster its pipeline and market position. Future targeted M&A could accelerate growth and diversify its product portfolio, mitigating patent cliff risks.
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 198,727 |
| Blackrock Inc. | 176,825 |
| State Street Corporation | 97,980 |
| JPMORGAN CHASE & CO | 75,367 |
| Charles Schwab Investment Management, Inc. | 71,322 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| MEYERS GREGORY SCOTT | Chief Technology Officer | Mar 10, 2026 | Award | 25,892 |
| SHANAHAN KARIN | Officer | Mar 10, 2026 | Award | 25,501 |
| LENKOWSKY ADAM | Officer | Mar 10, 2026 | Award | 24,071 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 2.5 |
⚠ Key Risk Factors
Multi-billion dollar revenue risk
Delayed revenue streams
Increased cost of capital
Eroding market share
🤔 Given the high probability of patent cliff exposure, how effectively can BMY’s current pipeline and M&A strategy truly mitigate this impending revenue challenge?
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $75.0 | $62.72 | $40.0 | 25 | Hold |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| HSBC | Hold | Mar 2026 | Maintains | |
| RBC Capital | Sector Perform | Feb 2026 | Initiates | |
| Piper Sandler | Overweight | Feb 2026 | Maintains | |
| Barclays | Overweight | Feb 2026 | Initiates | |
| Citigroup | Neutral | Feb 2026 | Maintains |
The consensus rating of 'Hold' from 25 analysts, with a mean target of $62.72, suggests limited near-term upside from current levels. This reflects a cautious stance on BMY’s immediate growth prospects, despite some firms initiating with ‘Overweight’ ratings.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Successful pipeline execution and new drug approvals significantly offset patent cliff impacts.
- Strategic acquisitions bolster growth, expanding BMY’s market presence in high-growth therapeutic areas.
📊 Base Case
Our base case anticipates BMY will continue to manage its patent cliff through cost controls and modest contributions from new launches, maintaining its dividend. Revenue will remain relatively stable, but significant growth will be challenging without a major pipeline breakthrough. This scenario implies a fair value reflecting its current earnings power and dividend yield.
🐻 Bear Case
- Key clinical trials fail, leaving significant gaps in the pipeline to counter patent expirations.
- Increased competition and pricing pressures erode market share faster than anticipated, impacting profitability.
🎯 Investor Action Plan — By Profile
Stay on the sidelines for now. Await a clear reclaim of $59.00 on above-average volume for a short-term bounce, or a dip towards $57.00 to capitalize on the bullish FVG retest.
Consider initiating a small position if BMY retests the $57.00 level or below, leveraging the strong technical confluence. Scale in gradually, acknowledging the long-term patent cliff risks.
For existing long-term holders, maintain your position. The attractive dividend yield and potential for pipeline successes justify holding, but monitor R&D updates closely for any shifts in the growth narrative.
❓ Investor FAQ — People Also Ask
Q: Is BMY’s dividend yield sustainable given its challenges?
BMY’s 4.30% dividend yield is currently supported by $1.6 billion in Free Cash Flow from its latest quarter. While patent expirations pose a long-term risk to earnings, the company’s strong cash generation provides a buffer for dividend payments in the near to medium term.
Q: How significant is the patent cliff for Bristol-Myers Squibb?
The patent cliff for blockbuster drugs like Opdivo and Eliquis represents a high-probability, high-impact risk for BMY. These drugs are major revenue contributors, and their loss of exclusivity could lead to substantial revenue declines, making pipeline success critical for future growth.
Q: Is BMY undervalued at its current price?
Trading at 16.9x earnings, BMY appears undervalued compared to the S&P 500 average (21x) and some growth-oriented peers. However, this valuation likely reflects the market’s concerns about the patent cliff and the uncertainty surrounding its future growth drivers. The $62.72 mean target suggests limited upside.
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. All data is accurate as of March 29, 2026, based on publicly available information.
All active positions and their real-time performance are tracked on our Investment Log.
#BMY #BristolMyersSquibb #HealthcareStocks #Pharma #StockAnalysis #DividendStocks #TechnicalAnalysis #WallStreet